Overdose with sodium zirconium cyclosilicate could lead to hypokalemia.L12822,F130
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent.L2933 It is administered orally and is odorless, tasteless, and stable at room temperature.L2933 Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration.L2933 The treatment effect was maintained for up to 12 months.L2933
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Atazanavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Sodium zirconium cyclosilicate. |
| Dabigatran etexilate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Sodium zirconium cyclosilicate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Dexmethylphenidate | Sodium zirconium cyclosilicate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Sodium zirconium cyclosilicate. |
| Captopril | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Sodium zirconium cyclosilicate. |
| Rifampin | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Memantine | Sodium zirconium cyclosilicate may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Sodium zirconium cyclosilicate. |
| Mesalazine | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolate mofetil | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Mycophenolate mofetil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The therapeutic efficacy of Tolevamer can be decreased when used in combination with Sodium zirconium cyclosilicate. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Sodium zirconium cyclosilicate. |
| Ketoconazole | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methenamine | The therapeutic efficacy of Methenamine can be decreased when used in combination with Sodium zirconium cyclosilicate. |
| Iron Dextran | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Prussian blue | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron sucrose | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Iron sucrose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric pyrophosphate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric ammonium citrate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxsil | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferumoxides | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric sulfate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous bisglycinate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gleptoferron | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Perflubutane | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous sulfate anhydrous | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferrous sulfate anhydrous resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sodium feredetate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric hydroxide | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric cation | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous gluconate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous succinate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferrous fumarate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tetraferric tricitrate decahydrate | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric oxyhydroxide | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric oxyhydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ferric maltol | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ferric maltol resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Iron polymaltose | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Iron polymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nelfinavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Nelfinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Indinavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Indinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ritonavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Ritonavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Amprenavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tipranavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Tipranavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Saquinavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Saquinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Darunavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Darunavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Fosamprenavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Fosamprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Lopinavir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Lopinavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Asunaprevir | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Asunaprevir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| TMC-310911 | Sodium zirconium cyclosilicate can cause a decrease in the absorption of TMC-310911 resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Sodium zirconium cyclosilicate can cause an increase in the absorption of Raltegravir resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Palbociclib | The absorption of Palbociclib can be decreased when combined with Sodium zirconium cyclosilicate. |
| Octreotide | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Octreotide resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Infigratinib | The serum concentration of Infigratinib can be decreased when it is combined with Sodium zirconium cyclosilicate. |
| Levoketoconazole | Sodium zirconium cyclosilicate can cause a decrease in the absorption of Levoketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Nirogacestat | The serum concentration of Nirogacestat can be decreased when it is combined with Sodium zirconium cyclosilicate. |